Privi Speciality Chemicals Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Turnaround confirmed, margins healing: After two bad quarters, gross margins improved sequentially as low-cost raw materials flowed through, power and freight costs fell, and yield enhancements from the new CAPEX kicked in.
• Volume growth of 20–25% is the headline, but value lags at ~10%: Contract prices dipped 12–14% YoY and the mix includes lower-priced Camphor, so the volume story is stronger than the revenue story.
• The ₹800 cr expansion is finally contributing: Camphor, Galaxmusk and Prionyl are now commercialized, customer approvals (including Christian Dior) are in hand, and calendar year 2024 is the first full year of bidding these products into annual contracts.
• Debt and inventory are coming down, but equity raise talk is back: Debt reduced from ₹1,145 cr to ₹950 cr and inventory by ₹200 cr, yet management flagged a possible rights issue or QIP for future growth plans once financial parameters improve.
• What to watch next quarter: Whether the Red Sea disruption creates a genuine demand spurt and spot price recovery, the pace of Camphor anti-dumping action, and any concrete news on the Givaudan JV commissioning timeline.

Turnaround Mechanics

• Raw material tailwind drove the margin recovery: High-cost inventory (CST, GTO imported with 60–120 day lead times) was mostly consumed by mid-August, so Q3 ran entirely on lower-cost raw materials. This, plus yield and process improvements from the new CAPEX, expanded gross margins without any increase in selling prices.
• Power and freight costs also eased: Coal costs came under control and freight contracts were renegotiated at lower rates, adding further support to the margin turnaround.
• The bad quarters are now a trailing drag: The Dec 2022 and Mar 2023 quarters (low sales, low margins) still weigh on trailing-twelve-month ROE and ROCE, but management expects both to reach mid-to-high teens by year-end as those quarters roll off.
• Spot market is the swing factor: Spot prices trended lower through mid-January but have begun picking up in the last 10 days. The Red Sea disruption may cause stockpiling and a demand spurt, though management does not expect a repeat of the 2022 scenario.

Rajan: "I don't think that we are going to witness a situation like we did in the past. Because commerce unites and it has to go on."

Volume vs Value: The Growth Gap

• Volume is growing 20–25%, but value only ~10%: Contract prices for calendar year 2024 were negotiated 12–14% below 2023 levels across several products, a global reality in the aroma chemical industry. Camphor adds ~3,000 tonnes of volume at a lower price point, widening the gap.
• Base business is near full: Pine-based legacy products are running at ~90% capacity, so only ~10% incremental volume can come from existing products. The 20% volume growth is entirely from new products (Galaxmusk, Camphor, Prionyl) where volumes were previously zero.
• Camphor faces a China dumping problem: Chinese players are dumping material into India at very low prices, suppressing Camphor margins. Privi is contemplating anti-dumping measures jointly with other Indian manufacturers.
• Galaxmusk pricing held up better: Unlike Camphor, Galaxmusk prices have not eroded much beyond what was planned and anticipated.
• Order book provides visibility: 70–75% of the calendar year order book is already booked, with orders coming in slightly above a pro rata basis.

Iyer: "We are now looking at sustaining and ensuring that we get back into our mold of growth, both in terms of volume, in terms of margins."

New Products & Customer Validation

• Three new products are now commercialized: Camphor (capitalized Sep 2022), Galaxmusk (Jun 2022), and Prionyl (Dec 2022) received government permissions in Jan/Feb 2023. Calendar year 2024 is the first full year they are being bid into annual contracts.
• Christian Dior approval is a milestone: Dior has approved Privi's products and commercial transactions will begin in the very near future. L'Oreal is another opportunity coming on board.
• FDA license secured for Camphor: This enabled Privi to successfully bid for Camphor contracts for the entire calendar year. The company is now focused on US FDA approval for pharma-grade Camphor, with some pharma companies having approved samples and others in the pipeline.
• All customer approvals obtained: Permissions and approvals from various customers for Galaxmusk, Prionyl, and Camphor are now in hand.
• Capacity utilization targets: Management expects 75–80% utilization for Galaxmusk, Camphor, and Prionyl, with Camphor volume targeted at 3,000–3,600 tonnes in FY24-25.

Margins: Sustainability & Trajectory

• Current margins are the new baseline: Management believes the September and December margin average (22–23%) is sustainable for calendar year 2024, with perhaps one or two basis points of variation depending on the spot market.
• Product mix will lift margins over time: As the product basket enlarges with more specialty products on the same cost base, margins will travel toward the positive side. Specialty products always enjoy higher margins and will cushion erosion in legacy products.
• Debottlenecking adds another lever: The company is studying and initiating steps to move legacy products from batch to continuous production, which would optimize existing assets and improve margins further.
• Management declined to disclose product-level margins: When asked for margin profiles of Galaxmusk, Camphor, and Prionyl individually at optimum utilization, management called it proprietary information and would only speak to the blended trajectory.

Iyer: "What margins we have shown in September and December, on an average, I believe this should be the margins going forward, maybe one, two basis point plus minus here and there."

Balance Sheet & Capital Allocation

• Debt reduced by ~₹195 cr from peak: Debt came down from ₹1,145 cr to ₹950 cr, and inventory from ₹870 cr to ₹690 cr, a reduction of about ₹200 cr in the last 12 months.
• Equity raise is on the table: Management said it may come to the market with a rights issue or QIP at an appropriate moment, after consolidating financials and getting closer to better financial parameters, to fund future growth plans. No specific timeline or amount was committed.
• Next CAPEX cycle is 2–3 years out: With total capacity of 45–47,000 metric tonnes, volume growth can continue for the next two years. By year three, new CAPEX will be needed, with a 12–15 month setup period. Future projects may include a menthol plant, benzyl salicylate, or other products mentioned by the Chairman at the AGM.
• Solar power savings began in January: Final permission from the Maharashtra government was obtained, and savings from the 26% equity participation in a solar power plant started flowing from January 2024 onward. The company is studying whether new state policies will allow it to increase solar dependence beyond 25%.

Strategic Initiatives & Sustainability

• Givaudan JV is progressing toward mid-2024 commissioning: The greenfield project is 60–70% complete, with infrastructure being set up. Water trials will begin with 5–10 products (out of an eventual 40) by June/July/August, with full commissioning expected between June and September.
• Menthol project is at pilot stage: Research and laboratory work was successful, and the project has been taken to pilot plant with good success. Continuous batches and innovations are ongoing. Management will return to the market when ready to set up the menthol plant, which it flagged as an appropriate time to raise equity.
• Sustainability credentials are strengthening: RSPO certification received, Sedex audit completed with no repeat non-conformities, TFS score at 85%, EcoVadis score at 65 (vs Indian average of 42%). EY has been engaged to guide the sustainability path, and upgrades to WHO GMP certification and CDP score are ongoing.
• Coal-free energy target: The company aims for at least 20–30% of its feed to be coal-free, using briquettes and moving forward.

Rajan: "Privi is, today, a juggernaut which will chug along no matter what and we are very positive about the outlook."

Guidance & Commitments

Key Metrics